Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.53B 11B 10.23B 9.39B 17.64B 1,206B 17.91B 122B 47.47B 593B 47.03B 46.01B 2,051B P/E 2026 *
-74.4x
P/E 2027 * 63.8x
Enterprise Value 12.01B 10.55B 9.81B 9B 16.92B 1,157B 17.18B 117B 45.52B 569B 45.09B 44.12B 1,966B EV / Sales 2026 *
8.02x
EV / Sales 2027 * 5.25x
Free-Float
94.11%
Yield 2026 *
-
Yield 2027 * -
1 day+0.21%
1 week-1.62%
Current month+1.41%
1 month+6.82%
3 months+6.27%
6 months+13.33%
Current year-6.50%
1 week 526.6
Extreme 526.605
555.05
1 month 505.63
Extreme 505.63
569.44
Current year 416.21
Extreme 416.21
598.79
1 year 286.44
Extreme 286.44
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 6.6
Extreme 6.6
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
20/7/26 Sell

Chief Executive Officer

-2,500 0.0108%
17/6/26 Free

Founder

1,220 0.0053%
17/6/26 Free

Director

1,220 0.0053%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-1.62%+82.01%+164.74% 12.53B
-1.92%-1.57%+48.70%+84.37% 55.92B
+0.93%+6.97%+62.83%+67.97% 56.67B
-2.97%-2.35%-22.03%-16.54% 23.28B
-0.46%-1.29%+3.28%+422.58% 23.28B
-0.36%-0.56%+36.00%-3.93% 20.54B
-1.34%-0.63%+29.60%-32.53% 17.78B
-1.44%-1.63%+37.07%+589.93% 15.9B
-1.30%-9.92%+160.67%+284.37% 14.64B
-0.50%-0.98%+23.62%+178.38% 13.99B
Average -0.92%+0.25%+46.18%+173.93% 25.45B
Weighted average by Cap. -0.83%+1.24%+44.84%+139.34%

Financials

2026 *2027 *
Net sales 1.5B 1.32B 1.22B 1.12B 2.11B 144B 2.14B 14.53B 5.68B 70.94B 5.63B 5.5B 245B 2.18B 1.91B 1.78B 1.63B 3.07B 210B 3.12B 21.14B 8.26B 103B 8.18B 8.01B 357B
Net income -210M -184M -171M -157M -295M -20.19B -300M -2.03B -794M -9.92B -787M -770M -34.31B 264M 232M 216M 198M 372M 25.41B 377M 2.56B 1B 12.49B 991M 969M 43.19B
Net Debt -515M -452M -421M -386M -725M -49.61B -737M -5B -1.95B -24.39B -1.93B -1.89B -84.33B -1.08B -945M -879M -806M -1.52B -104B -1.54B -10.44B -4.08B -50.94B -4.04B -3.95B -176B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
24/07/26 USD 544.51 +0.21% 147,388
23/07/26 USD 543.35 +1.06% 160,514
22/07/26 USD 537.65 -1.67% 310,899
21/07/26 USD 546.79 +2.07% 222,279
20/07/26 USD 535.69 -3.21% 223,809
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
544.51USD
Average target price
679.64USD
Spread / Average Target
+24.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock